The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan

British Journal of Haematology

Volumn 148, Issue 4, 2010, Pages 569-581

  Sanchez, Eric ^a   Li, Mingjie ^a   Steinberg, Jeffrey A ^a   Wang, Cathy ^a   Shen, Jing ^a   Bonavida, Benjamin ^b   Li, Zhi Wei ^a   Chen, Haiming ^a   Berenson, James R ^a  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bortezomib; CEP 18770; Melphalan; Multiple myeloma; Proteasome inhibitor

Indexed keywords

BORTEZOMIB; CEP 18770; LENALIDOMIDE; MELPHALAN; PROTEASOME INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BONE MARROW BIOPSY; CANCER INHIBITION; CANCER RESISTANCE; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; MALE; MONOTHERAPY; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; MALE; MELPHALAN; MICE; MICE, SCID; MULTIPLE MYELOMA; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; THREONINE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 75149157969     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.08008.x     Document Type: Article

References (42)

1. Ahn, K.S., Sethi, G., Chao, T.H., Neuteboom, S.T., Chaturvedi, M.M., Palladino, M.A., Younes, A. Aggarwal, B.B. (2007) Salinosporamide A (NPI-0052) potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through down-modulation of NF-kappaB regulated gene products. Blood, 110, 2286 2295. (Pubitemid 47523146)
2. Argyriou, A.A., Iconomou, G. Kalofonos, H.P. (2008) Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood, 112, 1593 1599.
3. Baumann, P., Mandl-Weber, S., Oduncu, F. Schmidmaier, R. (2008) Alkylating agents induce activation of NFkappaB in multiple myeloma cells. Leukemia Research, 32, 1144 1147.
4. Berenson, J.R., Yang, H.H., Sadler, K., Jarutirasarn, S.G., Vescio, R.A., Mapes, R., Purner, M., Lee, S.P., Wilson, J., Morrison, B., Adams, J., Schenkein, D. Swift, R. (2006) Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Journal of Clinical Oncology, 24, 937 944. (Pubitemid 46638848)
5. Berenson, J.R., Yang, H.H., Vescio, R.A., Nassir, Y., Mapes, R., Lee, S.P., Wilson, J., Yellin, O., Morrison, B., Hilger, J. Swift, R. (2008) Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Annals of Hematology, 87, 623 631.
6. Bianchi, G., Oliva, L., Cascio, P., Pengo, N., Fontana, F., Cerruti, F., Orsi, A., Pasqualetto, E., Mezghrani, A., Calbi, V., Palladini, G., Giuliani, N., Anderson, K.C., Sitia, R. Cenci, S. (2009) The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood, 113, 3040 3049.
7. Bissery, M.-C., Guenard, D., Gueritte-Voegelein, F. Lavelle, F. (1991) Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a taxol Analogue. Cancer Research, 51, 4845 4852.
8. Campbell, R.A. Berenson, J.R. 2008) Animal models of multiple myeloma and their utility in drug discovery. Current Protocols in Pharmacology, 40, 14.9.1 14.9.22 (unit 49. Hoboken, NJ: John Wiley & Sons, Inc.).
9. Campbell, R.A., Sanchez, E., Steinberg, J.A., Baritaki, S., Gordon, M., Wang, C., Shalitin, D., Chen, H., Pang, S., Bonavida, B., Said, J. Berenson, J.R. (2007) Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid. British Journal of Haematology, 138, 467 478.
10. Chauhan, D. Anderson, K.C. (2003) Mechanisms of cell death and survival in multiple myeloma (MM): therapeutic implications. Apoptosis, 8, 337 343.
11. Chauhan, D., Hideshima, T. Anderson, K.C. (2008a) Targeting proteasomes as therapy in multiple myeloma. Advances in Experimental Medicine and Biology, 615, 251 260.
12. Chauhan, D., Singh, A., Brahmandam, M., Podar, K., Hideshima, T., Richardson, P., Munshi, N., Palladino, M.A. Anderson, K.C. (2008b) Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood, 111, 1654 1664.
13. Chen, Q., Van der Sluis, P.C., Boulware, D., Hazlehurst, L.A. Dalton, W.S. (2005) The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood, 106, 698 705.
14. Chou, T.C. (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews, 58, 621 681.
15. Chou, T.C. Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27 55.
16. Crawford, L.J., Walker, B., Ovaa, H., Chauhan, D., Anderson, K.C., Morris, T.C. Irvine, A.E. (2006) Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Research, 66, 6379 6386.
17. Demo, S.D., Kirk, C.J., Aujay, M.A. Buchholz, T.J., Dajee, M., Ho, M.N., Jiang, J., Laidig, G.J., Lewis, E.R., Parlati, F., Shenk, K.D., Smyth, M.S., Sun, C.M., Vallone, M.K., Woo, T.M., Molineaux, C.J. Bennett, M.K. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Research, 67, 6383 6391.
18. Dorsey, B.D., Iqbal, M., Chatterjee, S., Menta, E., Bernardini, R., Bernareggi, A., Cassara, P.G., Arasmo, D.G., Ferretti, E., De Munari, S., Olivia, A., Pezzoni, G., Allievi, C., Strepponi, I., Ruggeri, B., Ator, M.A., Williams, M. Mallamo, J.P. (2008) Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer. Journal of Medicinal Chemistry, 51, 1068 1072.
19. Hamburger, A. Salmon, S.E. (1977) Primary bioassay of human myeloma stem cells. Journal of Clinical Investigation, 60, 846 854.
20. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. Anderson, K.C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 3071 3076.
21. Jacquemont, C. Taniguchi, T. (2007) Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Research, 67, 7395 7405.
22. Jagannath, S., Barlogie, B., Berenson, J., Siegel, D., Irwin, D., Richardson, P.G., Niesvizky, R., Alexanian, R., Limentani, S.A., Alsina, M., Adams, J., Kauffman, M., Esseltine, D.L., Schenkein, D.P. Anderson, K.C. (2004) A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. British Journal of Haematology, 127, 165 172.
23. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T. Thun, M.J. (2008) Cancer statistics. CA: A Cancer Journal for Clinicains, 58, 71 96.
24. Ma, M.H., Yang, H.H., Parker, K., Manyak, S., Friedman, J.M., Altamirano, C., Wu, Z.Q., Borad, M.J., Frantzen, M., Roussos, E., Neeser, J., Mikail, A., Adams, J., Sjak-Shie, N., Vescio, R.A. Berenson, J.R. (2003) The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clinical Cancer Research, 9, 1136 1144.
25. Matsui, W., Huff, C.A., Wang, Q., Malehorn, M.T., Barber, J., Tanhehco, Y., Smith, B.D., Civin, C.I. Jones, R.J. (2004) Characterization of clonogenic multiple myeloma cells. Blood, 103, 2332 2336.
26. Matsui, W., Wang, Q., Barber, J.P., Brennan, S., Smith, B.D., Borrello, I., McNiece, I., Lin, L., Ambinder, R.F., Peacock, C., Watkins, D.N., Huff, C.A. Jones, R.J. (2008) Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance. Cancer Research, 68, 190 197.
27. McConkey, D.J. Zhu, K. (2008) Mechanisms of proteasome inhibitor action and resistance in cancer. Drug Resistance Updates, 11, 164 179.
28. Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., Jack, H.M. Voll, R.E. (2007) Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Research, 67, 1783 1792.
29. Mitsiades, N., Mitsiades, C.S., Poulaki, V., Chauhan, D., Richardson, P.G., Hideshima, T., Munshi, N.C., Treon, S.P. Anderson, K.C. (2002) Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 99, 4525 4530.
30. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., Poulaki, V., Tai, Y.T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Schlossman, R., Munshi, N.C. Hideshima, K.C. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood, 101, 2377 2380.
31. Obeng, E.A., Carlson, L.M., Gutman, D.M., Harrington, Jr., W.J., Lee, K.P. Boise, L.H. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood, 107, 4907 4916.
32. Pei, X.Y., Dai, Y. Grant, S. (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clinical Cancer Research, 10, 3839 3852.
33. Pilarski, L.M., Seeberger, K., Coupland, R.W., Eshpeter, A., Keats, J.J., Taylor, B.J. Belch, A.R. (2002) Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID mice. Experimental Hematology, 30, 221 228.
34. Pineda-Roman, M., Zangari, M., van Rhee, F., Anaissie, E., Szymonifka, J., Hoering, A., Petty, N., Crowley, J., Shaughnessy, J., Epstein, J. Barlogie, B. (2008) VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia, 22, 1419 1427.
35. Piva, R., Ruggeri, B., Williams, M., Costa, G., Tamagno, I., Ferrero, D., Giai, V., Coscia, M., Peola, S., Massaia, M., Pezzoni, G., Allievi, C., Pescalli, N., Cassin, M., di Giovine, S., Nicoli, P., de Feudis, P., Strepponi, I., Roato, I., Ferracini, R., Bussolati, B., Camussi, G., Jones-Bolin, S., Hunter, K., Zhao, H., Neri, A., Palumbo, A., Berkers, C., Ovaa, H., Bernareggi, A. Inghirami, G. (2008) CEP-18770: a novel orally-active proteasome inhibitor with a tumor-selective pharmacological profile competitive with bortezomib. Blood, 111, 2765 2775.
36. Podar, K., Raab, M.S., Zhang, J., McMillin, D., Breitkreutz, I., Tai, Y.T., Lin, B.K., Munshi, N., Hideshima, T., Chauhan, D. Anderson, K.C. (2007) Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood, 109, 1669 1677.
37. Richardson, P.G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S.V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R.Z., Kuter, D., Limentani, S.A., Lee, S., Hideshima, T., Esseltine, D.L., Kauffman, M., Adams, J., Schenkein, D.P. Anderson, K.C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine, 348, 2609 2617.
38. Richardson, P.G., Sonneveld, P., Schuster, M., Irwin, D., Stadtmauer, E., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San Miguel, J., Blade, J., Boccadoro, M., Cavenagh, J. Anderson, K. (2006) Bortezomib demonstrates superior survival compared with high-dose dexamethasone and higher response rates after extended follow-up in the APEX trial in relapsed multiple myeloma. Haematologica, 91 (Suppl. 1 84. Abstract 224.
39. Roccaro, A.M., Hideshima, T., Raje, N., Kumar, S., Ishitsuka, K., Yasui, H., Shiraishi, N., Ribatti, D., Nico, B., Vacca, A., Dammacco, F., Richardson, P.G. Anderson, K.C. (2006) Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Research, 66, 184 191.
40. San Miguel, J.F., Schlag, R., Khuageva, N.K., Dimopoulos, M.A., Shpilberg, O., Kropff, M.H., Spicka, I., Petrucci, M.T., Palumbo, A., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.-V., Anderson, K.C., Esseltine, D.-L., Liu, K., Cakana, A., Van de velde, H. Richardson, P. (2008) Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma. Blood (ASH Annual Meeting Abstracts), 112, 650.
41. Sunters, A., Springer, C.J., Bagshawe, K.D., Souhami, R.L. Hartley, J.A. (1992) The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid. Biochemical Pharmacology, 44, 59 64.
42. Zweegman, S. Huijgens, P.C. (2002) Treatment of myeloma: recent developments. Anti-Cancer Drugs, 13, 339 351.